Details of the Drug Combination

General Information of Drug Combination (ID: DCVJ74G)

Drug Combination Name
Estramustine Topetecan
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs Estramustine   DMWTAOI Topetecan   DMAE6LK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SK-MEL-2
Zero Interaction Potency (ZIP) Score: 11.62
Bliss Independence Score: 15.42
Loewe Additivity Score: 0.2
LHighest Single Agent (HSA) Score: 9.19

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Estramustine
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
Estramustine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estramustine binding protein (EMBP) TTSBFYK NOUNIPROTAC Binder [4]
------------------------------------------------------------------------------------
Estramustine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Estramustine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [3]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCKAG1C MOLT-4 Investigative [8]
Breast adenocarcinoma DCDYNQG MDA-MB-468 Investigative [9]
Mixed endometrioid and clear cell carcinoma DC475B7 IGROV1 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4 Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.
5 Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
6 Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
7 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165